Communiqués IRLAB Therapeutics AB

Actions

IRLAB A

SE0012675361

Produits pharmaceutiques

Temps Différé Nasdaq Stockholm 16:17:59 22/09/2026			Varia. 5j.	Varia. 1 janv.
1,720 ^SEK	-1,15%		-6,11%	-12,69%

03/09	Irlab : la directrice générale Kristina Torfgård quittera ses fonctions en 2027	FW
03/09	La directrice générale d'Irlab, Kristina Torfgård, souhaite quitter ses fonctions	FW

Communiqués

03/09	IRLAB's CEO Intends to Step Down During the First Quarter of 2027	AQ
03/09	IRLAB’s CEO intends to step down during the first quarter of 2027	AQ
31/08	New number of shares and votes in IRLAB Therapeutics AB	AQ
26/08	IRLAB publishes interim report for the period January - June 2026	AQ
20/08	IRLAB: Invitation to the interim report for Q2 2026 presentation and webcast	AQ
19/08	IRLAB's Drug Candidate IRL757 Receives the Generic Name Linepemat from The WHO	AQ
19/08	IRLAB’s Drug Candidate IRL757 Receives the Generic Name linepemat from the WHO	AQ
31/07	New number of shares and votes in IRLAB Therapeutics AB	AQ
10/07	IRLAB Therapeutics : rights issue is registered – conversion of BTA into shares	PU
30/06	Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB	AQ
16/06	IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies	AQ
16/06	IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies	AQ
05/06	IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received	AQ
05/06	Report from the Extraordinary General Meeting of IRLAB Therapeutics AB	AQ
03/06	IRLAB Participates at Aktiedagarna in Stockholm on June 9	AQ
03/06	IRLAB participates at Aktiedagarna in Stockholm on June 9.	AQ
06/05	IRLAB Therapeutics : Financial Report (irlab q1 2026 eng final)	PU
06/05	IRLAB Therapeutics : publishes interim report for the period January – March 2026	PU
06/05	IRLAB publishes interim report for the period January - March 2026	AQ
05/05	IRLAB resolves on a rights issue of approximately SEK 68 million with an overallotment issue and obtains extended loan financing	AQ
30/04	IRLAB: Invitation to the interim report for Q1 2026 presentation and webcast	AQ
29/04	IRLAB publishes the Annual Report for 2025	AQ
17/04	Nomination Committee's proposal to the Board of Directors for IRLAB Therapeutics' Annual General Meeting 2026	AQ
17/04	Nomination Committee’s proposal to the Board of Directors for IRLAB Therapeutics’ Annual General Meeting 2026	AQ
09/04	IRLAB to present at Redeye Healthcare Day 2026	AQ